Market Overview:
The global chronic plaque psoriasis therapeutics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing prevalence of psoriasis, rising awareness about available treatment options, and technological advancements in the field of psoriasis therapeutics. Based on type, the global chronic plaque psoriasis therapeutics market is segmented into clinical and non-clinical segments. The clinical segment is further sub-segmented into systemic therapies and topical therapies. The systemic therapies sub-segment is further divided into biologics and small molecules. The topical therapies sub-segment includes corticosteroids, vitamin D analogs, tar products, anthralin products, calcineurin inhibitors (CNIs), tazarotene gel/creams/lotion 0·1%, ixekizumab injection 10 mg/mL solution for intravenous infusion (IVIxekizumab), secukinumab 150 mg solution for injection (Secukinumab) etc., while the non-clinical segment includes phototherapy devices and dietary supplements etc. Based on application, the global chronic plaque psoriasis therapeutics market is classified into hospitals & clinics settings; ambulatory surgical centers; other settings such as home care setting or long term care facilities; research institutes & contract research organizations (CROs).
Product Definition:
Chronic plaque psoriasis is a type of psoriasis that affects most of the body. It is characterized by red, raised patches of skin that are covered with silvery scales. These patches may be itchy or sore. The condition is often treated with topical medications, such as creams or ointments, and/or oral medications.
Clinical:
Clinical is a new term in the psoriasis therapeutics market. It means that the drug has been tested on humans and is expected to have similar results on animals before approval. The clinical phase of drug development includes proving that an active ingredient will do what it's supposed to do, without any unwanted side effects. This phase can last from 6 weeks to 3 years or more, depending upon the complexity of a particular medicine and its therapeutic profile.
Non-Clinical:
Non-clinical or basic research studies are those that do not involve human subjects and can be used for the development of drugs. The non-clinical data is crucial in aiding drug discovery processes as it provides information on pharmacokinetics, pharmacodynamics, and safety. Lack of such data often leads to failed drug development programs which can be a major setback for pharmaceutical companies especially small/medium enterprises with limited resources.
Application Insights:
The others segment held the largest share of the global chronic plaque psoriasis therapeutics market in 2017. This is due to factors such as increasing prevalence of skin diseases and growing aging population. The hospital segment is expected to grow at a lucrative rate during the forecast period owing to rising awareness about treatment options, availability of advanced healthcare facilities and government initiatives for controlling disease outbreaks.
Psoriasis affects approximately 20 million people in North America alone, thus providing ample opportunity for pharmaceutical companies developing new drugs for treatment purposes. For instance, Pfizer developed Enbrel (Taltz) using its pembro-kinase enzyme inhibitor technology platform in collaboration with Genome Institute Ltd., a company it acquired through merger with Astrazeneca group last year (2016). Enbrel was approved by U.
Regional Analysis:
North America held the largest share in 2017. The region is expected to maintain its dominance throughout the forecast period owing to increasing prevalence of chronic plaque psoriasis and rising healthcare expenditure. Moreover, growing number of product approvals and launch of new products by key companies are also contributing towards market growth in this region. For instance, In April 2018, Cipla Inc., a subsidiary of Cipla Ltd., received FDA approval for Uptravi HSD (calcipotriol) Tablets & Capsules formulation that contains 0.5% calcipotriene gel as active pharmaceutical ingredient for topical application in adults with psoriasis vulgaris who have been unresponsive to or intolerant of conventional therapy or who are candidates for phototherapy or surgery (U.S.).
Growth Factors:
- Increasing prevalence of chronic plaque psoriasis
- Growing awareness about chronic plaque psoriasis and its treatment options
- Rising demand for better and more effective therapies for chronic plaque psoriasis
- increasing investment in research and development of new therapies for chronic plaque psoriasis 5. Availability of novel therapies with improved efficacy and safety profiles
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Plaque Psoriasis Therapeutics Market Research Report
By Type
Clinical, Non-Clinical, Inactive
By Application
Hospitals, Ambulatory Surgical Centers, Others
By Companies
Abbvie, Novartis International, Pfizer, Merck, Astelllas Pharma, GlaxoSmithKline
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Plaque Psoriasis Therapeutics Market Report Segments:
The global Chronic Plaque Psoriasis Therapeutics market is segmented on the basis of:
Types
Clinical, Non-Clinical, Inactive
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbvie
- Novartis International
- Pfizer
- Merck
- Astelllas Pharma
- GlaxoSmithKline
Highlights of The Chronic Plaque Psoriasis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Clinical
- Non-Clinical
- Inactive
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Plaque Psoriasis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic plaque psoriasis therapeutics is a term used to describe treatments for psoriasis that are intended to slow or stop the progression of the disease. These treatments may include medications, phototherapy, and surgery.
Some of the key players operating in the chronic plaque psoriasis therapeutics market are Abbvie, Novartis International, Pfizer, Merck, Astelllas Pharma, GlaxoSmithKline.
The chronic plaque psoriasis therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Plaque Psoriasis Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chronic Plaque Psoriasis Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chronic Plaque Psoriasis Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chronic Plaque Psoriasis Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chronic Plaque Psoriasis Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Chronic Plaque Psoriasis Therapeutics Market Size and Y-o-Y Growth
4.5.2 Chronic Plaque Psoriasis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Chronic Plaque Psoriasis Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Type
5.2.1 Clinical
5.2.2 Non-Clinical
5.2.3 Inactive
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chronic Plaque Psoriasis Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Plaque Psoriasis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chronic Plaque Psoriasis Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Type
9.6.1 Clinical
9.6.2 Non-Clinical
9.6.3 Inactive
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chronic Plaque Psoriasis Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Type
10.6.1 Clinical
10.6.2 Non-Clinical
10.6.3 Inactive
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chronic Plaque Psoriasis Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Type
11.6.1 Clinical
11.6.2 Non-Clinical
11.6.3 Inactive
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chronic Plaque Psoriasis Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Type
12.6.1 Clinical
12.6.2 Non-Clinical
12.6.3 Inactive
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chronic Plaque Psoriasis Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Type
13.6.1 Clinical
13.6.2 Non-Clinical
13.6.3 Inactive
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chronic Plaque Psoriasis Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Plaque Psoriasis Therapeutics Market: Competitive Dashboard
14.2 Global Chronic Plaque Psoriasis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbvie
14.3.2 Novartis International
14.3.3 Pfizer
14.3.4 Merck
14.3.5 Astelllas Pharma
14.3.6 GlaxoSmithKline
